Noven at sector perform by RBC

Noven Pharmaceuticals Inc. was given a rating of sector perform, above average risk, by RBC Capital Markets analyst Ken Trbovich. The analyst is not convinced that early growth trends can be sustained over the longer term because of the possible Food and Drug Administration approval (Oct. 6, 2006) and launch of NRP-104 in early 2007. In particular, questions remain as to the sales potential of Daytrana considering the potential entry of a major new product in the ADHD category. Shares of the Miami-based pharmaceutical company were up $1.22, or 5.72%, at $22.56, on volume of 516,744 shares versus the three-month running average of 208,142 shares. (Nasdaq: NOVN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.